Navalign LLC Sells 11,327 Shares of Pfizer Inc. (NYSE:PFE)

Navalign LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 44.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 14,221 shares of the biopharmaceutical company’s stock after selling 11,327 shares during the period. Navalign LLC’s holdings in Pfizer were worth $409,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. State Street Corp increased its position in shares of Pfizer by 1.9% during the second quarter. State Street Corp now owns 287,201,692 shares of the biopharmaceutical company’s stock worth $10,534,558,000 after acquiring an additional 5,374,611 shares in the last quarter. Moneta Group Investment Advisors LLC increased its position in shares of Pfizer by 89,592.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after acquiring an additional 160,963,976 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Pfizer by 10.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after acquiring an additional 9,393,992 shares in the last quarter. Morgan Stanley increased its position in shares of Pfizer by 0.4% during the third quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock worth $2,817,055,000 after acquiring an additional 348,628 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Pfizer during the fourth quarter worth about $3,150,472,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of PFE stock traded down $0.03 during trading on Thursday, reaching $27.75. 39,620,254 shares of the company’s stock traded hands, compared to its average volume of 43,835,094. The company has a market capitalization of $157.14 billion, a P/E ratio of 77.08, a PEG ratio of 1.24 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The firm’s 50-day moving average is $27.46 and its 200 day moving average is $29.46. Pfizer Inc. has a 1 year low of $25.61 and a 1 year high of $42.22.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. Pfizer’s revenue was down 41.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.14 EPS. Equities research analysts expect that Pfizer Inc. will post 2.22 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on PFE. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. UBS Group reduced their price objective on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a research report on Thursday, December 14th. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research report on Thursday, January 4th. Guggenheim began coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Finally, Truist Financial reduced their price objective on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, December 14th. Twelve investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus target price of $36.88.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.